Dr. David Juncker
Rosalind and Morris Goodman Cancer Research Centre
The Research Institute of the McGill University Health Centre
David received a fellowship from the Swiss Academy of Engineering Sciences for a one year internship at the National institute of Metrology of Japan from 1997-1998. In 2006, David was awarded a Canada Research Chair in Micro- and Nanobioengineering, which was renewed in 2011. In 2012, he was further honoured by being selected as Young Scientist by the IAP - the global network of science academies - and asked to represent Canada at the World Economic Forum, the Summer Davos New Champions Meeting in Tianjin, China, Sept 10-15th, 2012. In 2013, David Juncker was awarded a fellowship from the German Cancer Research Centre (DKFZ) and became a visiting scientist in Dr. Jörg Hoheisel's Functional Genome Analysis division at the DKFZ in Heidelberg.
David stayed as a visiting scientist at the National Metrology Institute of Japan in Tsukuba from 1997-98. He conducted his PhD research at the IBM Zurich Research Laboratory from 1999-2002. He then pursued his studies as a Post-doc first at IBM Zurich until 2004, and then one year at the Swiss Federal Institute of Technology in Zurich (ETH). David started as an assistant professor in the Biomedical Engineering Department of McGill University in 2005, was promoted to associate professor with tenure in 2011, and became a full professor in 2016. As of early 2018, David serves as departmental chair of the Biomedical Engineering Department at McGill University.
David's current interests are in the miniaturization and integration in biology and medicine, which includes
the engineering and utilization of novel micro and nanotechnologies for manipulating, stimulating and studying oligonucleotides, proteins, cells, and tissues. The emerging field of nanobiotechnology, in a broad sense, is the most exciting to David, and is also key to tackle some of the major challenges in biology and medicine, for example identifying novel biomarkers for early disease diagnosis and developing low-cost point-of-care diagnostics.